Xeris Pharmaceuticals to Announce First Quarter 2021 Financial Results and Host Conference Call and Webcast on May 13, 2021
May 06 2021 - 4:05PM
Business Wire
Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty
pharmaceutical company leveraging its novel formulation technology
platforms to develop and commercialize ready-to-use injectable and
infusible drug formulations, today announced that the Company will
release its first quarter 2021 financial results before the open of
the U.S. financial markets on Thursday, May 13, 2021. Management
will host a conference call and webcast at 8:30 a.m. ET that day to
discuss the Company’s financial and operational results.
To register for the conference call please use this link:
http://www.directeventreg.com/registration/event/8668322. After
registering, a confirmation email will be sent, including dial-in
details and a unique code for entry. The Company recommends
registering at minimum ten minutes prior to the start of the call.
Following the conference call, a replay will be available at (800)
585-8367 or (416) 621-4642 Conference ID: 8668322.
About Xeris Pharmaceuticals, Inc.
Xeris (Nasdaq: XERS) is a specialty pharmaceutical company
delivering innovative solutions to simplify the experience of
administering important therapies that people rely on every day
around the world.
With a novel technology platform that enables ready-to-use,
room-temperature stable formulations of injectable and infusible
therapies, the company is advancing a portfolio of solutions in
various therapeutic categories, including its first commercial
product, Gvoke®. Its proprietary XeriSol™ and XeriJect™ formulation
technologies have the potential to offer distinct advantages over
conventional product formulations, including eliminating the need
for reconstitution, enabling long-term, room-temperature stability,
significantly reducing injection volume, and eliminating the
requirement for intravenous (IV) infusion. With Xeris’ technology,
new product formulations are designed to be easier to use by
patients, caregivers, and health practitioners and help reduce
costs for payers and the healthcare system.
Xeris is headquartered in Chicago, IL. For more information,
visit www.xerispharma.com, or follow us on Twitter, LinkedIn or
Instagram.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210506005211/en/
Investor Contact Allison Wey Senior Vice President,
Investor Relations and Corporate Communications
awey@xerispharma.com 312-736-1237
Xeris Biopharma (NASDAQ:XERS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Xeris Biopharma (NASDAQ:XERS)
Historical Stock Chart
From Apr 2023 to Apr 2024